Back

Circulating levels of erythrocytes-derived vesicles related to poor glycaemia control in heart failure patients with type 2 diabetes mellitus

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - biomarkers 2 Biomarkers HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Alexander E Berezin

Paracelsus Private Medical University, Salzburg (Austria)

6 More presentations in this session

Presentation thumbnail
Fibrosis-4 index may predict long-term mortality in patients admitted for acute decompensated heart failure
Associate Professor B. MURAT (Eskisehir, TR)
Abstract Slides Video
Presentation thumbnail
Proteomic profiles of left atrial volume and its influence on response to spironolactone: findings from the HOMAGE trial and STANISLAS cohort
Doctor M. Kobayashi (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Increased serum PRO-C3 is associated with heart failure worsening in hypertensive patients with heart failure
Mr I. Latasa Amezqueta (Pamplona, ES)
Abstract Slides Video
Presentation thumbnail
Normal troponin T and NTproBNP values effectively rule-out cardiac amyloidosis in patients with prior bilateral surgery for carpal tunnel syndrome.
Doctor N. Noory (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Pro-adrenomedullin may guide decongestive therapy in acute heart failure patients
Doctor B. Beer (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - biomarkers 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Circulating levels of erythrocytes-derived vesicles related to poor glycaemia control in type 2 diabetes mellitus patients with atrial fibrillation
thumbnail
Congress Presentation
Erythrocyte-derived extracellular vesicles from type 2 diabetes patients induce endothelial dysfunction through arginase 1
thumbnail
Congress Presentation
Incidence of erythrocytosis and thromboembolic risk in patients with heart failure and reduced ejection fraction treated with SGLT2 Inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources